Joint Clinical Assessment (JCA): A harmonised approach to clinical assessments across the European Union
In January 2022, the European Commission published a milestone regulation enforcing a joint approach to clinical assessments across the European Union. This joint clinical assessment (JCA) of technologies will begin with oncology therapies in January 2025. Here, we outline the upcoming JCA process and give some thoughts to its benefits and drawbacks. At HEOR, we look forward to using our HTA experience to support our clients in strategically navigating this new landscape and aiding patient access to life-changing medicines.
Click here to download the full white paper.